- Home
- TRNR vs GOVX Comparison
TRNR vs GOVX Comparison
Compare TRNR & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRNR | GOVX |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 3.8M |
| IPO Year | 2023 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TRNR | GOVX |
|---|---|---|
| Price | $3.04 | $0.46 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 10.4K | ★ 668.0K |
| Earning Date | 05-18-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,530,000.00 | $2,489,145.00 |
| Revenue This Year | $264.92 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 114.31 | N/A |
| 52 Week Low | $0.19 | $0.12 |
| 52 Week High | $12.12 | $4.40 |
Technical Indicators
Market Signals| Indicator | TRNR | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 29.17 |
| Support Level | $2.67 | $0.14 |
| Resistance Level | $3.83 | $0.86 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 3.62 | 3.65 |
Price Performance
Historical ComparisonAbout TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.